Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754274 | 0.88 | KMT2A (0.44) | KMT2APPARAMEN1MAPTPOLB | |
| SCHEMBL16978138 | 0.85 | KMT2A (0.52) | KMT2AMEN1MAPT | |
| SCHEMBL18931471 | 0.85 | KMT2A (0.52) | KMT2AMEN1MAPT | |
| SCHEMBL17758731 | 0.84 | CA12 (0.47) | KMT2AMEN1MAPTABCG2 | |
| SCHEMBL21702644 | 0.82 | KMT2A (0.39) | KMT2APPARAMEN1MAPTPOLB | |
| SCHEMBL22099221 | 0.81 | TDP1 (0.41) | KMT2AMEN1MAPTPOLBABCG2 | |
| SCHEMBL17433324 | 0.81 | KMT2A (0.56) | KMT2AMEN1MAPT | |
| SCHEMBL17719444 | 0.81 | NFKB1 (0.40) | KMT2AMEN1MAPTPOLB | |
| SCHEMBL22099234 | 0.80 | TDP1 (0.46) | KMT2APPARAMEN1MAPTPOLB | |
| SCHEMBL18960025 | 0.80 | KMT2A (0.53) | KMT2APPARAMEN1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | DIC CORPORATION (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137921-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION PRODUCED USING SAME | RCC1, LPXN, SMC4 | KMT2A 2308/4885PPARA 4099/4885MEN1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.